313 related articles for article (PubMed ID: 37334349)
1. The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients.
Mao MQ; Ding YX; Jing J; Tang ZW; Miao YJ; Yang XS; Chen YH; Chen SZ; Wu XJ; Lu ZF
Front Immunol; 2023; 14():1195858. PubMed ID: 37334349
[TBL] [Abstract][Full Text] [Related]
2. Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.
Liu M; Gao Y; Yuan Y; Yang K; Shen C; Wang J; Tian J
JAMA Netw Open; 2023 Jun; 6(6):e2320351. PubMed ID: 37368402
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
Wei D; Chen Y; Shen Y; Xie B; Song X
Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis.
Barati Sedeh F; Michaelsdóttir TE; Henning MAS; Jemec GBE; Ibler KS
Acta Derm Venereol; 2023 Jan; 103():adv00855. PubMed ID: 36695751
[TBL] [Abstract][Full Text] [Related]
5. Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.
Papierzewska M; Waśkiel-Burnat A; Rudnicka L
Clin Drug Investig; 2023 May; 43(5):325-334. PubMed ID: 37138134
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase inhibitors for alopecia areata: A narrative review.
Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of JAK inhibitors in the treatment of alopecia areata in children: a systematic review and meta-analysis.
Chen Y; Zhu H; Shen Y; Zhu Y; Sun J; Dai Y; Song X
J Dermatolog Treat; 2022 Dec; 33(8):3143-3149. PubMed ID: 36214579
[TBL] [Abstract][Full Text] [Related]
8. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
9. The Evolving Story of JAK Inhibitors for Treating Alopecia Areata: A Review of Current Progress and Future Directions.
Donovan J
Skin Therapy Lett; 2023 May; 28(3):1-7. PubMed ID: 37339501
[TBL] [Abstract][Full Text] [Related]
10. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
Ramot Y; Zlotogorski A
Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C; Yang X; Yang B; Yan G; Dong X; Ding Y; Fan W; Li L; Yang D; Fang H; Ji C; Cheng H; Zhang S; Goh AH; Liu R; Gu X; Weng Z; Foley P; Sinclair R; Zhang J
J Am Acad Dermatol; 2023 Nov; 89(5):911-919. PubMed ID: 37019385
[TBL] [Abstract][Full Text] [Related]
12. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
Eisman S; Sinclair R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase inhibitors for alopecia areata.
King BA; Craiglow BG
J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
[TBL] [Abstract][Full Text] [Related]
14. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
Stefanis AJ
Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
[TBL] [Abstract][Full Text] [Related]
15. [Janus kinase inhibitors for the treatment of alopecia areata].
Kobal I; Ramot Y
Hautarzt; 2022 May; 73(5):336-343. PubMed ID: 35482047
[TBL] [Abstract][Full Text] [Related]
16. Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors.
Paggioli I; Moss J
J Autoimmun; 2022 Dec; 133():102926. PubMed ID: 36335798
[TBL] [Abstract][Full Text] [Related]
17. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.
Mikhaylov D; Glickman JW; Del Duca E; Nia J; Hashim P; Singer GK; Posligua AL; Florek AG; Ibler E; Hagstrom EL; Estrada Y; Rangel SM; Colavincenzo M; Paller AS; Guttman-Yassky E
Arch Dermatol Res; 2023 Mar; 315(2):181-189. PubMed ID: 35230488
[TBL] [Abstract][Full Text] [Related]
18. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
[TBL] [Abstract][Full Text] [Related]
19. Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B; Ohyama M; Kwon O; Zlotogorski A; Ko J; Mesinkovska NA; Hordinsky M; Dutronc Y; Wu WS; McCollam J; Chiasserini C; Yu G; Stanley S; Holzwarth K; DeLozier AM; Sinclair R;
N Engl J Med; 2022 May; 386(18):1687-1699. PubMed ID: 35334197
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata.
King B; Mesinkovska N; Mirmirani P; Bruce S; Kempers S; Guttman-Yassky E; Roberts JL; McMichael A; Colavincenzo M; Hamilton C; Braman V; Cassella JV
J Am Acad Dermatol; 2022 Aug; 87(2):306-313. PubMed ID: 35364216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
